ArticleJournal of translational medicine2026
FBXO39 promotes LDHA-mediated aerobic glycolysis and colorectal cancer progression by p53 degradation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Ubiquitination modification is extensively involved in various biological processes, including aerobic glycolysis and tumor development. TP53 mutations are present in nearly half of CRC patients, while in p53-wild type CRC, effective therapeutic targets remain relatively limited.
methodsWe employed bioinformatics methods to systematically analyze the expression and prognostic value of E3 ubiquitin ligase FBXO family members in CRC, with a focus on FBXO39. Through in vitro experiments such as CCK-8 assay, EdU cell proliferation assay, colony formation assay, glucose metabolite measurement, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) analyses, as well as in vivo experiments including cell-derived xenograft models, we elucidated the biological functions of FBXO39 in CRC. Furthermore, we explored its molecular mechanisms through molecular docking, co-immunoprecipitation (Co-IP), and ubiquitination assays.
resultsFBXO39 expression was significantly higher in CRC tissues than in adjacent normal tissues, and its high expression was associated with poor patient prognosis. Functional experiments demonstrated that FBXO39 significantly promoted CRC cell proliferation both in vitro and in vivo. Mechanistically, FBXO39 directly bound to the p53 protein and promoted its ubiquitination-mediated degradation in p53-wild type CRC cells. Further investigations revealed that FBXO39 overexpression enhanced the aerobic glycolysis capacity of CRC cells, while its knockdown inhibited this process. Mechanistically, FBXO39 enhanced aerobic glycolysis and promoted tumor cell proliferation by upregulating lactate dehydrogenase A (LDHA) expression in a p53-dependent manner.
conclusionThis study reveals a novel mechanism for p53 protein downregulation in p53-wild type CRC, elucidates the role of FBXO39 in regulating aerobic glycolysis through the p53/LDHA axis to promote tumor progression, and provides new insights into the function of FBXO39 in metabolic reprogramming in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.